跳至主要内容
临床试验/EUCTR2021-003162-12-PL
EUCTR2021-003162-12-PL进行中(未招募)1 期

A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects with Idiopathic Pulmonary Fibrosis

CSL Behring LLC0 个研究点目标入组 80 人开始时间: 2022年3月14日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Male or female patients, = 40 years of age
  • 2. Documented diagnosis of IPF
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 40
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 40

排除标准

  • 1. History of clinically significant cardiovascular disease, including myocardial infarction, unstable ischemic heart disease, congestive heart failure, or angina
  • 2. Sinoatrial or atrioventricular block, uncontrolled hypertension
  • 3. Active bleeding or current clinically significant coagulopathy

研究者

相似试验

进行中(未招募)
1 期
CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary FibrosisMedDRA version: 21.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: SOCClassification code 10038738Term: Respiratory, thoracic and mediastinal disordersSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersIdiopathic Pulmonary Fibrosis
EUCTR2021-003162-12-ATCSL Behring LLC80
进行中(未招募)
1 期
CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
EUCTR2021-003162-12-DKCSL Behring LLC80
进行中(未招募)
1 期
CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary FibrosisMedDRA version: 21.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: SOCClassification code 10038738Term: Respiratory, thoracic and mediastinal disordersSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersIdiopathic Pulmonary Fibrosis
EUCTR2021-003162-12-DECSL Behring LLC80
进行中(未招募)
1 期
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys With Duchenne Muscular DystrophyMedDRA version: 20.0 Level: PT Classification code 10013801 Term: Duchenne muscular dystrophy System Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular Dystrophy
EUCTR2016-001654-18-ESBristol-Myers Squibb International Corporation160
进行中(未招募)
1 期
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular DystrophyDuchenne Muscular Dystrophy
EUCTR2016-001654-18-NLF. Hoffmann-La Roche Ltd166